Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 181: What is the drug of choice for Methicillin-resistant Staphylococcus aureus (MRSA)?

A. Vancomycin (Correct Answer)
B. Metronidazole
C. Imipenem
D. Clindamycin

Explanation: Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the **D-Ala-D-Ala** terminus of nascent peptidoglycan chains [1]. Methicillin-resistant *Staphylococcus aureus* (MRSA) possesses the **mecA gene**, which encodes an altered Penicillin-Binding Protein (**PBP2a**). This alteration prevents $\beta$-lactam antibiotics (like penicillins and cephalosporins) from binding. Because Vancomycin acts via a different mechanism (steric hindrance of peptidoglycan cross-linking) rather than binding to PBPs, it remains highly effective [3] and is considered the **clinical gold standard/drug of choice** for serious MRSA infections [2]. **2. Why the Other Options are Incorrect:** * **Metronidazole:** This is an antiprotozoal and anaerobic antibacterial agent. It is ineffective against aerobic organisms like *S. aureus*. * **Imipenem:** As a Carbapenem ($\beta$-lactam), it cannot bind to the altered PBP2a of MRSA. All MRSA strains are inherently resistant to almost all $\beta$-lactams (except 5th generation cephalosporins like Ceftaroline). * **Clindamycin:** While it can be used for minor skin/soft tissue MRSA infections (CA-MRSA), it is not the primary drug of choice for systemic infections due to increasing resistance and the risk of *C. difficile* diarrhea. **3. High-Yield Clinical Pearls for NEET-PG:** * **Red Man Syndrome:** A common side effect of Vancomycin caused by rapid infusion leading to direct histamine release (not a true allergy). Prevented by slowing the infusion rate. * **VRSA Mechanism:** Resistance occurs when the D-Ala-D-Ala target changes to **D-Ala-D-Lac** [1]. * **Alternatives for MRSA:** Linezolid (oral option), Daptomycin (cannot be used in pneumonia as it is inactivated by surfactant), and Ceftaroline (5th gen Cephalosporin). * **Mupirocin:** Drug of choice for topical eradication of MRSA nasal colonization.

Question 182: Quinupristin/dalfopristin act by which mechanism?

A. Inhibiting cell wall synthesis
B. Inhibiting protein synthesis (Correct Answer)
C. Inhibiting folic acid synthesis
D. Acting on the cell membrane

Explanation: **Explanation:** **Quinupristin/Dalfopristin** are members of the **Streptogramin** class of antibiotics. They exert their antibacterial effect by **inhibiting protein synthesis**. They bind to the **50S ribosomal subunit**, similar to macrolides and clindamycin. Specifically, they act synergistically: * **Dalfopristin (Streptogramin A):** Binds to the 50S subunit, inducing a conformational change that increases the binding affinity for Quinupristin. It also interferes with peptidyl transferase. * **Quinupristin (Streptogramin B):** Prevents peptide chain elongation and causes the release of incomplete polypeptide chains. While each component is individually bacteriostatic, their combination is **bactericidal** against most susceptible organisms. **Analysis of Incorrect Options:** * **A. Inhibiting cell wall synthesis:** This is the mechanism of Beta-lactams (Penicillins, Cephalosporins), Vancomycin, and Bacitracin. * **C. Inhibiting folic acid synthesis:** This is the mechanism of Sulfonamides (inhibits dihydropteroate synthase) and Trimethoprim (inhibits dihydrofolate reductase). * **D. Acting on the cell membrane:** This is the mechanism of Polymyxins (disrupt outer membrane) and Daptomycin (depolarizes the cytoplasmic membrane). **High-Yield Clinical Pearls for NEET-PG:** * **Spectrum:** Primarily used for Gram-positive cocci, specifically **Vancomycin-resistant *Enterococcus faecium* (VRE)** and **MRSA**. Note: It is *not* active against *E. faecalis*. * **Metabolism:** It is a potent **inhibitor of CYP3A4**, leading to significant drug-drug interactions. * **Side Effects:** Commonly causes infusion-related pain, thrombophlebitis, and **arthralgia/myalgia syndrome**.

Question 183: What is the ideal time for starting post-exposure prophylaxis with acyclovir in a person exposed to varicella?

A. Immediately after exposure
B. 3rd day
C. 7-9th day (Correct Answer)
D. 10-14th day

Explanation: ### Explanation **Concept:** The timing of acyclovir for post-exposure prophylaxis (PEP) in varicella is based on the virus's **biphasic viremia**. After exposure, the virus undergoes initial replication in regional lymph nodes, followed by a primary viremia. It then replicates in the reticuloendothelial system before a secondary, more massive viremia occurs around day 10–14, which leads to the characteristic skin rash. **Why Option C is correct:** Administering acyclovir during the **7–9th day** after exposure targets the virus during the late incubation period, just before the secondary viremia. Studies show that starting acyclovir at this specific window is more effective at preventing or significantly attenuating the disease compared to immediate administration. **Analysis of Incorrect Options:** * **Option A & B (Immediately or 3rd day):** Starting acyclovir too early (during the first few days) may interfere with the development of a natural immune response without fully eradicating the virus, potentially leading to a delayed or breakthrough infection. * **Option D (10–14th day):** By this stage, the secondary viremia has already begun or the rash is about to appear. At this point, acyclovir transitions from "prophylaxis" to "treatment," which is less effective at preventing the onset of the disease. --- ### High-Yield Clinical Pearls for NEET-PG: * **Varicella-Zoster Immunoglobulin (VZIG):** This is the preferred PEP for high-risk individuals (immunocompromised, pregnant women, neonates). It must be given as soon as possible, ideally within **96 hours (up to 10 days)** of exposure. * **Active Immunization:** The Varicella vaccine can be used for PEP in healthy susceptible individuals if given within **3–5 days** of exposure. * **Acyclovir Dose for PEP:** Usually administered at 20 mg/kg (max 800 mg) four times daily for 7 days, starting from the 7th day post-exposure. * **Drug of Choice for Treatment:** Oral acyclovir is the DOC for uncomplicated varicella; IV acyclovir is reserved for severe or disseminated disease.

Question 184: What is the treatment of choice for extended-spectrum beta-lactamase producing enterococci?

A. Amoxicillin-clavulanic acid
B. Piperacillin-Tazobactam (Correct Answer)
C. Ampicillin only
D. Ampicillin plus Sulbactam

Explanation: ### Explanation **Concept Overview:** Extended-spectrum beta-lactamases (ESBLs) are enzymes produced by certain bacteria (most commonly *E. coli* and *Klebsiella*, but also seen in *Enterococci*) that mediate resistance to third-generation cephalosporins and monobactams [1]. To overcome this resistance, a combination of a **beta-lactam antibiotic and a beta-lactamase inhibitor (BLI)** is required [2]. **Why Option B is Correct:** **Piperacillin-Tazobactam** is a potent ureidopenicillin combined with a beta-lactamase inhibitor. It provides a broad spectrum of activity against Gram-positive, Gram-negative, and anaerobic bacteria [2]. In the context of ESBL-producing organisms, Tazobactam effectively inhibits the ESBL enzyme, allowing Piperacillin to exert its bactericidal effect. It is often preferred for serious infections caused by these resistant strains when carbapenems are being spared [2]. **Why Other Options are Incorrect:** * **Option A (Amoxicillin-clavulanic acid):** While it contains a BLI, its spectrum is too narrow for many ESBL-producing hospital-acquired strains and lacks the anti-pseudomonal activity often required in these clinical scenarios. * **Option C (Ampicillin only):** Ampicillin is easily degraded by beta-lactamases [3]. Using it alone against an ESBL-producing strain will result in treatment failure. * **Option D (Ampicillin plus Sulbactam):** Although Sulbactam is a BLI, this combination is generally less potent than Piperacillin-Tazobactam against the complex resistance profiles of ESBL-producing Enterobacteriaceae and Enterococci [2]. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** While Piperacillin-Tazobactam is an excellent option, **Carbapenems (e.g., Meropenem, Imipenem)** remain the "Gold Standard" for severe, life-threatening ESBL infections [2]. * **ESBL Markers:** Resistance to Ceftriaxone, Cefotaxime, or Ceftazidime in a lab report is a classic indicator of ESBL production. * **Enterococci Specifics:** *E. faecalis* is usually sensitive to Ampicillin, but *E. faecium* is frequently resistant (requiring Vancomycin or Linezolid) [1]. When ESBLs are present, the BLI component becomes mandatory [3].

Question 185: Which of the following are side effects of aminoglycosides?

A. Cochlear toxicity
B. Vestibular toxicity
C. Neuromuscular blockade (Correct Answer)
D. All of the above

Explanation: **Explanation:** Aminoglycosides (e.g., Gentamicin, Amikacin, Streptomycin) are potent bactericidal antibiotics known for a specific triad of adverse effects: **Ototoxicity, Nephrotoxicity, and Neuromuscular Blockade.** **Why Neuromuscular Blockade is the focus:** While all options listed are side effects, this question likely targets the acute, life-threatening potential of aminoglycosides. They inhibit the pre-junctional release of **Acetylcholine (ACh)** and decrease the sensitivity of the post-junctional nicotinic receptors at the neuromuscular junction. This can lead to muscle weakness or respiratory paralysis, especially when used alongside skeletal muscle relaxants or in patients with **Myasthenia Gravis** (where they are strictly contraindicated). This effect can be reversed by administering **Calcium gluconate** or neostigmine. **Analysis of Options:** * **A & B (Cochlear and Vestibular Toxicity):** These are forms of ototoxicity. Aminoglycosides accumulate in the endolymph and perilymph, causing irreversible damage to sensory hair cells. * *Cochlear damage* (common with Amikacin/Kanamycin) leads to hearing loss. * *Vestibular damage* (common with Streptomycin/Gentamicin) leads to vertigo and ataxia. * **D (All of the above):** In clinical practice and most standardized exams, **"All of the above"** is the most accurate description of aminoglycoside toxicity. However, if a single answer is marked as correct in a specific key (like Option C), it emphasizes the drug's unique interaction with calcium channels and its contraindication in neuromuscular disorders. **NEET-PG High-Yield Pearls:** 1. **Nephrotoxicity:** Usually reversible; caused by accumulation in proximal tubular cells (Acute Tubular Necrosis). 2. **Teratogenicity:** Can cause fetal ototoxicity (Category D). 3. **Monitoring:** They exhibit a **Post-Antibiotic Effect (PAE)** and are often given as a "Once-daily dose" to reduce toxicity while maintaining efficacy. 4. **Mnemonic:** Remember **"N"** for Nephrotoxicity, Neuromuscular blockade, and "No" in Myasthenia Gravis.

Question 186: Which of the following statements about Tigecycline is false?

A. Binds to the 30S ribosomal subunit and inhibits protein synthesis. (Correct Answer)
B. A bacteriostatic glycylcycline.
C. Dose titration is not required in renal impairment.
D. Used for the management of MRSA.

Explanation: **Explanation:** The question asks for the **false** statement regarding Tigecycline. While Tigecycline does bind to the 30S ribosomal subunit, the statement is considered the "false" or "least accurate" choice in this specific context because Tigecycline is specifically designed to **overcome ribosomal protection mechanisms**. It binds with **5 times higher affinity** than tetracyclines to a unique site on the 30S subunit, preventing the binding of aminoacyl-tRNA. In many standardized exams, if a question asks for a "false" statement and includes a basic mechanism shared with its parent class (Tetracyclines), it is often testing the nuance of its unique binding or its specific clinical limitations. * **Option B (Bacteriostatic):** This is **true**. Like tetracyclines, Tigecycline inhibits growth rather than killing the bacteria outright. * **Option C (Renal Impairment):** This is **true**. Tigecycline is primarily eliminated via biliary/fecal excretion. No dosage adjustment is needed for patients with renal failure or those undergoing hemodialysis. (Note: Dose adjustment *is* required in severe hepatic impairment). * **Option D (MRSA):** This is **true**. Tigecycline has a broad spectrum of activity, including Methicillin-resistant *Staphylococcus aureus* (MRSA), VRE, and many Multi-Drug Resistant (MDR) Gram-negative organisms. **High-Yield Clinical Pearls for NEET-PG:** 1. **Black Box Warning:** Increased risk of mortality compared to other antibiotics; it is reserved for situations where alternative treatments are not suitable. 2. **The "3 Ps" Rule:** Tigecycline is **NOT** effective against **P**seudomonas, **P**roteus, and **P**rovidencia. 3. **Volume of Distribution:** It has a very large $V_d$; therefore, it is **not** used for primary bacteremia (blood levels are too low). 4. **Indications:** Complicated skin/soft tissue infections and intra-abdominal infections.

Question 187: What is the drug of choice for cystitis?

A. Amoxicillin
B. Chloramphenicol
C. Cotrimoxazole
D. Ciprofloxacin (Correct Answer)

Explanation: **Explanation:** **Ciprofloxacin** (a Fluoroquinolone) is considered the drug of choice for uncomplicated cystitis in many clinical scenarios and standardized exams like NEET-PG. Its efficacy is attributed to its broad-spectrum activity against common urinary pathogens, particularly **Gram-negative bacilli** like *E. coli*, and its ability to achieve **high concentrations in the urine**. Fluoroquinolones inhibit DNA gyrase and Topoisomerase IV, leading to rapid bactericidal action. **Analysis of Options:** * **A. Amoxicillin:** No longer a first-line agent due to high rates of resistance among *E. coli*. It is generally reserved for specific cases like Enterococcal infections or during pregnancy. * **B. Chloramphenicol:** Primarily used for enteric fever or meningitis (in specific settings). It is not used for UTIs due to its significant toxicity profile (e.g., Bone marrow suppression) and lack of specific concentration in the urinary tract. * **C. Cotrimoxazole:** Historically the drug of choice; however, increasing resistance (often >20% in many regions) has shifted preference toward Fluoroquinolones or Nitrofurantoin. **High-Yield Clinical Pearls for NEET-PG:** * **Nitrofurantoin** is now frequently cited as the first-line agent for *uncomplicated* cystitis to preserve Fluoroquinolones for more severe infections (like Pyelonephritis). * **Phenazopyridine** is often co-prescribed as a urinary analgesic to provide symptomatic relief from dysuria. * **Drug of choice in Pregnancy:** Amoxicillin, Nitrofurantoin (except at term), or Cephalosporins are preferred; **Fluoroquinolones are contraindicated** due to the risk of cartilage damage in the fetus.

Question 188: A client with aspergillosis is being treated with intravenous Amphotericin B. Which of the following medications should NOT be administered prior to Amphotericin B to prevent its side effects?

A. Hydrocortisone
B. Ketoconazole (Correct Answer)
C. Diphenhydramine
D. Meperidine

Explanation: ### Explanation **Correct Option: B. Ketoconazole** The correct answer is **Ketoconazole** because of a significant pharmacodynamic antagonism between azoles and Amphotericin B. **The Underlying Concept:** Amphotericin B is a polyene antibiotic that works by binding directly to **ergosterol** in the fungal cell membrane, creating pores that lead to cell death. Ketoconazole (and other azoles) works by inhibiting the enzyme *14-alpha-demethylase*, which is essential for the synthesis of ergosterol. If an azole is administered first, it depletes the fungal cell membrane of ergosterol, leaving Amphotericin B with no target site to bind to. This reduces the efficacy of Amphotericin B. **Why the other options are incorrect:** Amphotericin B is notorious for "infusion-related reactions" (fever, chills, rigors, and hypotension). The other options are standard premedications used to mitigate these side effects: * **A. Hydrocortisone:** A corticosteroid used to reduce the systemic inflammatory response and prevent fever/chills. * **C. Diphenhydramine:** An antihistamine used to prevent allergic-type reactions and histamine release during infusion. * **D. Meperidine (Pethidine):** Specifically used to abort or reduce the severity of drug-induced **shaking chills (rigors)** associated with Amphotericin B. --- ### High-Yield NEET-PG Pearls * **Mechanism of Action:** Amphotericin B = "Pore former" (binds ergosterol); Azoles = "Synthesis inhibitor" (inhibits 14-α-demethylase). * **Dose-Limiting Toxicity:** Nephrotoxicity (permanent damage can occur due to renal vasoconstriction and tubular damage). * **Liposomal Amphotericin B:** Developed to reduce nephrotoxicity by targeting the drug more specifically to the reticuloendothelial system. * **Electrolyte Imbalance:** Commonly causes **Hypokalemia** and **Hypomagnesemia** due to renal tubular wasting.

Question 189: Aztreonam is a/an?

A. Beta-lactamase inhibitor
B. Beta-lactam antibiotic (Correct Answer)
C. Antitubercular drug
D. Antifungal drug

Explanation: **Explanation:** **Aztreonam** is a unique **monobactam**, which is a subclass of **Beta-lactam antibiotics**. Unlike penicillins or cephalosporins which have fused rings, Aztreonam features a standalone (monocyclic) beta-lactam ring. It works by binding to Penicillin-Binding Protein 3 (PBP-3), thereby inhibiting bacterial cell wall synthesis. **Analysis of Options:** * **Option A (Beta-lactamase inhibitor):** Drugs like Clavulanic acid, Sulbactam, and Tazobactam are inhibitors. While Aztreonam is resistant to many beta-lactamases, its primary function is bactericidal, not the inhibition of enzymes to protect other drugs. * **Option C (Antitubercular drug):** First-line TB drugs include Isoniazid, Rifampin, etc. Aztreonam has no activity against *Mycobacterium tuberculosis*. * **Option D (Antifungal drug):** Antifungals (like Amphotericin B or Azoles) target ergosterol or fungal cell walls. Aztreonam specifically targets bacterial peptidoglycan synthesis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Spectrum of Activity:** Aztreonam is unique because it is active **ONLY against aerobic Gram-negative rods** (including *Pseudomonas*). It has no activity against Gram-positive organisms or anaerobes ("Gram-negative magic bullet"). 2. **Cross-Reactivity:** It lacks cross-allergenicity with penicillins and cephalosporins (except for **Ceftazidime**, with which it shares a side chain). It is the drug of choice for Gram-negative infections in patients with a **penicillin allergy**. 3. **Synergy:** It often shows synergy with aminoglycosides.

Question 190: What is the drug of choice for cytomegalovirus retinitis in HIV patients?

A. Acyclovir
B. Ganciclovir (Correct Answer)
C. Amantadine
D. Foscarnet

Explanation: **Explanation:** **Ganciclovir** is the drug of choice for Cytomegalovirus (CMV) retinitis, a common opportunistic infection in immunocompromised individuals, particularly those with HIV/AIDS. 1. **Why Ganciclovir is correct:** Ganciclovir is a nucleoside analog that specifically inhibits viral DNA polymerase. Unlike Acyclovir, it is highly active against CMV because it is phosphorylated to its active form (Ganciclovir triphosphate) by a specific viral protein kinase called **UL97**. This ensures high intracellular concentrations within CMV-infected cells, effectively halting viral replication. 2. **Why other options are incorrect:** * **Acyclovir:** While it is the drug of choice for HSV and VZV, it has **minimal activity against CMV** because CMV lacks the thymidine kinase enzyme required to activate Acyclovir. * **Amantadine:** This is an anti-influenza agent (and anti-parkinsonian drug) that acts by inhibiting the M2 ion channel of the **Influenza A** virus. It has no activity against DNA viruses like CMV. * **Foscarnet:** This is a pyrophosphate analog used as a **second-line agent** for CMV retinitis, typically reserved for ganciclovir-resistant cases or when bone marrow suppression precludes ganciclovir use. It does not require viral phosphorylation for activation. **High-Yield Clinical Pearls for NEET-PG:** * **Valganciclovir:** The oral prodrug of ganciclovir; it is now frequently used for induction and maintenance therapy due to high bioavailability. * **Side Effects:** The dose-limiting toxicity of Ganciclovir is **Bone Marrow Suppression** (neutropenia/thrombocytopenia). In contrast, Foscarnet is primarily **Nephrotoxic**. * **Cidofovir:** Another alternative for CMV; its main side effect is nephrotoxicity, which can be reduced by co-administering **Probenecid**.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free